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Abstract
Objective In California, leukemia represents *35, 5, and
2% of all cancers in children (aged 0–14), adolescents (15–
29), and young adults (30–39), respectively. Poorer sur-
vival has been previously noted in individuals residing
in lower socioeconomic status (SES) neighborhoods. We
explored the relationship between SES and survival as
modiﬁed by age and race/ethnicity using data from the
California Cancer Registry.
Methods A total of 7,688 incident cases of ﬁrst primary
leukemia diagnosed during 1996–2005 in individuals aged
0–39 at diagnosis were included in this study. Univariate
analyses of overall survival were conducted using the
Kaplan–Meier method and multivariate survival analyses
were performed using Cox proportional hazard regression
to estimate hazard ratios.
Results Multivariate analyses showed that overall sur-
vival and lymphoid cancer–speciﬁc survival was reduced
in those individuals aged 15–39 compared to children aged
0–14. Although shorter survival was observed in non-
whites, an association between lower-SES neighborhood
and shorter survival was signiﬁcant only for non-Hispanic
whites (NHWs) (p value for trend \0.05). Lack of insur-
ance was signiﬁcantly associated with shorter survival for
all race/ethnicities examined except Asian/Paciﬁc Islanders
(p value\0.05).
Conclusion Lower survival in individuals diagnosed with
leukemia was observed in adolescents and young adults
compared to children and in non-whites compared to
NHWs. Further, the independent effects on survival of both
low SES and lack of insurance at diagnosis persisted after
adjustment for demographic variables and varied across
race/ethnicities.
Keywords Leukemia  Survival analysis 
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Introduction
In California, leukemia represents *34.9, 4.9, and 2.4% of
all cancers in individuals aged 0–14, 15–29, and 30–39,
respectively. For adolescents aged 15–19, leukemia is the
fourth leading type of cancer, with *746 new cases
diagnosed each year in California [1].
Marked differences in cancer incidence and survival
by race/ethnicity persist. Although non-Hispanic whites
(NHWs) have the highest overall cancer incidence rate, this
group also experiences the highest overall cancer survival
rate [2–4]. In California, Hispanics/Latinos are dispropor-
tionately affected in certain cancers. Hispanics aged 15–19
have twice the incidence rate of leukemia than NHWs
[1, 3] and experience a survival rate at least 7% lower than
NHWs [3].
The rapid progression of acute leukemias may present
challenges in accessing care when compared to other
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Access to clinical trials [5], availability of quality treatment
[6], availability of support systems [7], and having ade-
quate health insurance [8] have all been shown to be pos-
itively associated with neighborhood socioeconomic status
(nSES) and survival, and nSES may mediate the race/eth-
nicity survival relationship [9, 10]. Further, ﬁnancial con-
siderations may inﬂuence an individual’s decision to seek
and maintain cancer treatment [11].
Although adolescents and young adults (AYAs) have
been variably deﬁned, the National Cancer Institute prefers
the inclusive age span of 15–39. Using this designation,
leukemia represents the third most common cancer in
AYAs and the most common cancer type in younger
children [12]. Leukemia survival is improving for AYAs
[13], but survival remains worse for AYAs than for chil-
dren [14, 15], and little attention has been paid to possible
socioeconomic disparities in survival among these age
groups. The objectives of the present study were to
examine the relative inﬂuences of neighborhood socio-
economic status as modiﬁed by age at diagnosis, race/
ethnicity, and insurance status at diagnosis on overall
survival and leukemia-speciﬁc survival using population-
based cancer registry data.
Patients and methods
Study population
We performed a retrospective case-only analysis of all
leukemia cases diagnosed between the age of 0 and
39 years in California from 1996 to 2005 using the Cali-
fornia Cancer Registry (CCR) database (n = 7,688).
1 The
CCR is part of the National Cancer Institute’s Surveillance,
Epidemiology and End Results (SEER) program, with
standardized data collection and quality control protocols
in place since 1988 [16–19]. Both case reporting and fol-
low-up completion rates are higher than 95% for the entire
state of California [20]. After data are abstracted from
medical and laboratory records by trained tumor registrars
[18], tumor site and histology are coded according to the
World Health Organization’s criteria in International
Classiﬁcation of Diseases for Oncology (ICD-O, 3rd edi-
tion) [21].
For this analysis, patient cases were selected based on
histologic types for leukemias (SEER primary site codes
35000–35999) according to ICD-O-3: acute lymphocytic
leukemia (ALL; 9800, 9801, 9820, 9827, 9831–9834),
acute myeloid leukemia (AML; 9805, 9860, 9870, 9891,
9930, 9931, 9940, 9948, 9964), chronic myeloid leukemia
(CML; 9863, 9875, 9876, 9945, 9946, 9963), and all other
morphologies (other; 9733). Although chronic lymphocytic
leukemia (CLL; 9823) is considered one of the four pri-
mary types of leukemia, it is commonly seen only in
patients over the age of 65 and there were only 89 diag-
noses (\0.01%) that ﬁt our eligibility criteria. Therefore,
CLL cases were excluded from all subsequent analyses
beyond descriptive statistics.
Analyses were conducted on cases diagnosed between
1996 and 2005. Type of reporting source was available for
each case, with 33 cases identiﬁed only through death
certiﬁcate and nine cases identiﬁed through autopsy alone.
The remaining cases were identiﬁed through high-quality
reporting sources (hospital, inpatient/outpatient centers,
oncology treatment centers, laboratories, or private practi-
tioners). The CCR adheres to SEER standards, which
require annual follow-up of patients to ensure that survival
rates are as accurate as possible [18]. The registrars use both
passive follow-up methods (annual record linkages with
sources including the California State Death File, National
Death Index, Social-Security Death Master File, Medicare,
and Medicaid) as well as active follow-up (contact with
physicians’ ofﬁces, hospitals, and patient families). The
observation period ended at the end of 2005 because for this
dataset, cause of death could only be veriﬁed by death
certiﬁcate for cases deceased before the end of 2005.
Recorded data included age at diagnosis, demographic
information, histology, treatment during the ﬁrst course of
therapy, nSES, vital status, treatment hospital type (pedi-
atric or otherwise), and insurance status. Race and ethnicity
(Hispanic/Latino or not) are abstracted from patients’
medical records following the coding procedures outlined
by the CCR [18]. The nSES variable used in the CCR is a
single index created from statewide census data measures
of education, income, and occupation, previously described
[22]. The variable was created from a principle component
analysis of census block group-level data, including med-
ian educational attainment, median household income,
proportion below 200% of the federal poverty level,
median house value, median rent, percent employed, and
proportion of the population with blue-collar employment.
Quintiles for the nSES score were included for analysis.
Cause of death
Cause of death was recorded according to the International
Classiﬁcation of Disease (ICD) criteria in effect at the time
of death [21], using the ICD-9 codes for deaths prior to
2000 and ICD-10 codes for deaths in 2000 and later.
Hospital registrars contact cases annually and CCR staff
review state death certiﬁcates on an annual basis to identify
1 This study was approved by the University of California, Irvine
Institutional Review Board (IRB) under the exempt category status
(IRB# 2008-6236).
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was either the date of death or the last date of contact.
Lymphoid and hematopoietic cancer–speciﬁc deaths
included codes 204.0–208.9 and C810–C959 [23].
Statistical analyses
Demographic characteristics and clinical parameters were
analyzed using Pearson’s v
2 test and analysis of variance
(ANOVA) for comparing continuous variables across more
than two groups. Life tables and Kaplan–Meier curves were
generated for age group, race/ethnicity, nSES categories,
and insurance status and were compared with the log-rank
test. Cox proportional hazard regression was performed to
generate adjusted hazard ratios (HRs) for overall survival
(OS) and lymphoid/hematopoietic cancer–speciﬁc survival
(LSS) using SAS 9.1 (SAS Institute, Inc., Cary, NC), con-
trolling for race/ethnicity, leukemia type, nSES, insurance
status, gender, and year of diagnosis. Analyses stratiﬁed by
age group (0–14, 15–29, and 30–39), race/ethnicity [NHW,
non-Hispanic black (NHB), Hispanic/Latino (HL), Asian/
Paciﬁc Islander (API)], and leukemia type (ALL, AML,
CML) were also conducted to investigate effect modiﬁca-
tion on any nSES effects on survival. Treatment hospital
type (pediatric, pediatric afﬁliate, or other) was included for
the stratiﬁed age-group analysis. Statistical signiﬁcance was
assumed for a two-tailed p = 0.05.
Results
Demographic data
Of the 7,688 incident ﬁrst primary leukemias diagnosed
from 1996 to 2005 and included in the analysis, there were
2,689 NHWs, 389 NHBs, 3,760 HLs, and 778 APIs.
Demographic data for the entire patient population are
presented in Table 1. There was signiﬁcant variation in
diagnostic types by age group, with children aged 0–14
accounting for the majority of ALL (3,409, 72.6%,
p\0.0001),afairlyeven distributionamongagegroups for
AML,andyoungadultsaged30–39comprisingthemajority
of CLL (79, 88.8%, p\0.0001), and CML (421, 55.0%,
p\0.0001) cases. Hispanics/Latinos comprised the largest
number of ALL cases (2,542, 54.1%, p\0.0001), while
NHWs accounted for the most cases in all other subtypes.
Overall and for each individual subtype, the number of male
cases outnumbered female cases (p\0.0001) (Table 1).
Univariate analysis
Kaplan–Meier survival curves for overall survival by age
group, race/ethnicity, nSES, and insurance status were
generated (Fig. 1). Overall univariate survival was lower in
AYAs than in children (p\0.001), non-whites than in
NHWs (p\0.001), in lower nSES groups than in higher
ones (p\0.001), and in those without insurance or with
unknown insurance status at diagnosis compared to those
with any insurance (p\0.001). Figure 2 shows 5-year
survival rates by age at diagnosis. Excluding infant leu-
kemias (aged 0–1; believed to have a different etiologic
proﬁle from leukemias that develop later in life [24]),
survival rates appear to be higher in children. From age ﬁve
to *15–16, survival rates and overall survival times
decline with some leveling off in older individuals.
Neighborhood socioeconomic and insurance status
analysis
Signiﬁcant distributional variation (p\0.001) among the
ﬁve nSES quintiles for different race/ethnicities exists:
*26.9% of NHWs and 27.8% of APIs but only 5.2% of
HLs and 6.0% of NHBs belong to the highest quintile.
Conversely, 45.5% of HLs and 23.6% of NHBs but only
8.3% of NHWs and 12.1% of APIs belong to the poorest
nSES quintile. Approximately 45.5% of uninsured cases
and 38.7% of cases with unknown insurance status resided
in one of the lowest nSES quintile areas, compared to only
26.0% of cases with any insurance (p\0.001). On the
contrary, only 7.3% of the uninsured and 9.7% of those
with unknown insurance status lived in the highest nSES
quintile area at diagnosis, compared to 16.2% of cases with
any of type insurance.
Insurance status rates by race/ethnicity and 5-year age at
diagnosis groups were examined. Hispanics/Latinos had
the highest proportion of being uninsured at diagnosis
(HLs: 6.5%, NHBs: 3.5%, APIs: 3.1%, NHWs: 1.8%) with
statistically signiﬁcant differences among race/ethnic
groups (p\0.001). There was also a sharp rise in the
proportion of uninsured from individuals aged 15–19
(6.6%) to those aged 20–24 (11.0%), possibly explained by
the stipulations of most policies permitting minors to be
covered by parental insurance policies, as well as college
insurance plans. For subsequent multivariate survival
analyses, individuals with unknown insurance status were
combined with uninsured cases, as the univariate survival
curves for these two groups appeared to overlap (Fig. 1).
Cause of death analysis
Veriﬁed cause of death was available for patients through
2005. Of the 7,688 cases of leukemia examined for these
analyses, 2,194 had died by the end of 2005. Of those
deaths, 1,990 (90.7%) were due to neoplasms of the lym-
phoid or hematopoietic tissue and 17 (0.8%) were the result
of other cancer-related causes. As of this analysis, cause of
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common causes of death were infectious and parasitic
diseases (n = 37) and other respiratory diseases (n = 16).
Multivariate survival analysis
Overall survival and leukemia–speciﬁc survival analyses
were conducted using multivariate Cox regression models
that included sex, age group, leukemia type, race/ethnicity,
insurance status, and nSES (Table 2). After adjusting for
all other variables, HLs and NHBs had a signiﬁcantly
increased adjusted risk of death compared with NHWs.
Age group differences in survival persisted after adjust-
ment for all other variables. Individuals aged 15–29 had
increased risk of death compared to children aged 0–14,
with adults aged 30–39 having an even greater increased
risk of death. Neighborhood socioeconomic status assign-
ment signiﬁcantly contributed to risk of death after
adjustment for other variables. Trends for increasing risk of
mortality with declining nSES were signiﬁcant (OS:
p = 0.01, LSS: p = 0.007; Table 2). The combined not
insured/unknown insurance status group also had signiﬁ-
cantly increased mortality risk after adjustment for all other
variables.
Table 1 Demographic information and incidence for the major leukemia subtypes, for ﬁrst primary diagnoses
Characteristic Acute
lymphocytic
n = 4,695
n (%)
Acute
myeloid
n = 2,137
n (%)
Chronic
lymphocytic
n = 89
n (%)
Chronic
myeloid
n = 765
n (%)
Total
n = 7,688
n (%)
p
Age at diagnosis
0–14 3,409 (72.6) 675 (31.6) 2 (2.3) 72 (9.4) 4,158 (54.1) \0.0001
15–29 877 (18.7) 700 (32.8) 8 (9.0) 272 (35.6) 1,857 (24.2)
30–39 409 (8.7) 762 (35.7) 79 (88.8) 421 (55.0) 1,673 (21.8)
Mean age (SD) 10.6 (10.1) 21.6 (12.6) 34.5 (6.3) 28.1 (9.5) 15.7 (12.7) \0.0001
Year of diagnosis
1996–1999 1,811 (38.6) 881 (28.9) 34 (38.2) 328 (42.9) 3,054 (39.7) 0.035
2000–2003 1,889 (40.2) 848 (27.5) 42 (47.2) 307 (9.9) 3,087 (40.2)
2004–2005 995 (21.2) 408 (19.1) 13 (14.6) 130 (17.0) 1,547 (20.1)
Gender
Male 2,747 (58.5) 1,155 (54.1) 495 (64.7) 56 (62.9) 4,454 (57.9) \0.0001
Female 1,948 (41.5) 982 (46.0) 270 (35.3) 33 (37.1) 3,234 (42.1)
Race/ethnicity
Non-Hispanic white 1,529 (32.6) 810 (37.9) 50 (56.2) 300 (39.2) 2,689 (35.0) \0.0001
Non-Hispanic black 178 (3.8) 149 (7.0) 7 (7.9) 54 (7.1) 389 (5.1)
Hispanic/Latino 2,542 (54.1) 915 (42.8) 16 (18.0) 287 (37.5) 3,760 (48.9)
Asian/Paciﬁc Islander 408 (8.7) 252 (11.8) 7 (7.9) 110 (14.4) 778 (10.1)
Other 38 (0.8) 11 (0.5) 9 (10.1) 14 (1.8) 72 (0.9)
nSES
Highest 721 (15.4) 319 (14.9) 24 (27.0) 125 (16.3) 1,189 (15.5) \0.0001
High 768 (16.4) 381 (17.8) 20 (22.5) 157 (20.5) 1,327 (17.3)
Middle 830 (17. 7) 415 (19.4) 20 (22.5) 156 (20.4) 1,421 (18.5)
Low 995 (21.2) 476 (22.3) 18 (20.2) 140 (18.3) 1,630 (21.2)
Lowest 1,381 (29.4) 546 (25.6) 7 (7.9) 187 (24.4) 2,121 (27.6)
Insurance
Managed care or private insurance 2,630 (56.0) 1,175 (55.0) 72 (80.9) 453 (59.2) 4,331 (56.3) \0.0001
Medicaid/Medicare/government assistance 1,496 (31.9) 637 (29.8) 10 (11.2) 185 (24.2) 2,329 (30.3)
Tricare/military/Veterans Affairs 66 (1.4) 34 (1.6) 0 11 (1.4) 111 (1.4)
Not insured 177 (3.8) 118 (5.5) 2 (2.3) 46 (6.0) 343 (4.5)
Unknown 326 (6.9) 173 (8.1) 5 (5.6) 70 (9.2) 574 (7.5)
Source: California Cancer Registry. Individuals diagnosed between 1 January 1996 and 31 December 2005
SD standard deviation, nSES neighborhood socioeconomic status
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Multivariate survival analyses were repeated for each of
the three age groups (Table 3). As overall survival and
leukemia–speciﬁc survival rates were quite similar, only
OS rates are reported. Adjusted hazard ratios differed
between the four race/ethnicity groups, with a wider spread
for the group aged 0–14 than the older groups. In children,
larger adjusted HRs were evident for AML and CML when
compared to ALL. For individuals aged 30–39, a diagnosis
of AML or CML was associated with a lower risk of death
than a diagnosis of ALL. Only adjusted HRs for nSES
maintained a signiﬁcant gradient for AYAs aged 30–39
(p value for trend = 0.02). After controlling for other risk
factors, not having insurance or having unknown insurance
status signiﬁcantly increased risk of death in subjects
aged 0–14 (p\0.001) and 15–29 (p = 0.03), but was not
signiﬁcant in those aged 30–39 (p = 0.119).
Race/ethnicity-speciﬁc multivariate survival analysis
Multivariate survival analyses stratiﬁed by the four major
race/ethnicity groups demonstrated its importance as an
effect modiﬁer of nSES (Table 4). Survival was shorter for
each decreasing nSES quintile for NHWs, and this trend
was statistically signiﬁcant (p\0.05). Although the anal-
yses showed that survival was worse for NHBs in the lower
nSES groups (second poorest nSES-adjusted HR: 1.99,
95% CI: 0.78–5.04; poorest nSES-adjusted HR: 2.23, 95%
CI: 0.87–5.68), the adjusted hazard ratios were not statis-
tically signiﬁcant, which may be due to low overall num-
bers for this group. Asian/Paciﬁc Islanders residing in low
nSES neighborhoods also had signiﬁcantly worse survival
than those residing in the highest nSES neighborhoods
(poorest nSES-adjusted HR: 1.65, 95% CI: 1.06–2.56).
No signiﬁcant difference among neighborhood nSES on
survival was observed for HLs.
Table 2 Multivariate hazard ratios comparing overall survival (OS) and lymphoid/hematopoietic cancer-speciﬁc survival (LSS) using Cox
proportional hazards model
Characteristic OS LSS
HR (95% CI) p HR (95% CI) p
Age group
0–14 1.00 (Ref) – 1.00 (Ref) –
15–29 2.65 (2.38–2.95)* \0.0001 2.68 (2.39–3.00)* \0.0001
30–39 2.91 (2.58–3.29)* \0.0001 3.01 (2.65–3.42)* \0.0001
Race/ethnicity
Non-Hispanic White 1.00 (Ref) – 1.00 (Ref) –
Non-Hispanic Black 1.47 (1.22–1.76)* \0.0001 1.56 (1.29–1.88)* \0.0001
Hispanic/Latino 1.22 (1.09–1.36)* 0.0003 1.22 (1.09–1.37)* 0.0005
Asian/Paciﬁc Islander 1.18 (1.02–1.37)* 0.0311 1.20 (1.02–1.41)* 0.0241
Leukemia type
ALL 1.00 (Ref) – 1.00 (Ref) –
AML 1.46 (1.32–1.61)* \0.0001 1.44 (1.30–1.60)* \0.0001
CML 0.64 (0.55–0.75)* \0.0001 0.62 (0.52–0.73)* \0.0001
nSES
Highest 1.00 (Ref)  – 1.00 (Ref)  –
High 1.10 (0.94–1.29) 0.2374 1.18 (0.99–1.39)* 0.0591
Middle 1.19 (1.02–1.39)* 0.0298 1.24 (1.05–1.47)* 0.0110
Low 1.20 (1.03–1.40)* 0.0215 1.27 (1.07–1.49)* 0.0055
Lowest 1.31 (1.13–1.54)* 0.0006 1.37 (1.16–1.61)* 0.0002
Insurance
Any 1.00 (Ref) – 1.00 (Ref) –
None/unknown 1.31 (1.16–1.47)* 0.0001 1.27 (1.12–1.44)* 0.0002
Source: California Cancer Registry. Individuals diagnosed between January 1, 1996-December 31, 2005
nSES neighborhood socioeconomic status, OS overall survival, HR hazard ratio, CI conﬁdence interval, Ref reference
All hazard ratios are fully adjusted for the other variables in the model, in addition to gender and diagnostic year
Results for individuals with race/ethnicity other than what is listed (n = 63) are suppressed from output
OS: n = 7,597, with 5,410 observations censored; LSS: n = 7,597, with 5,613 observations censored
* Signiﬁcant at p\0.05;   signiﬁcant for trend, p\0.05
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Multivariate survival analyses were repeated for each of
the three main diagnostic types (Table 5). Subjects diag-
nosed with ALL between the age of 30 and 39 had 6.94
times higher hazard of death (95% CI: 5.91–8.14) and
subjects aged 15–29 had 3.90 times higher hazard of death
(95% CI: 3.40–4.48) than the youngest age group, after
adjusting for other risk factors. By race/ethnicity, non-
Hispanic blacks with ALL had the largest adjusted HR:
1.70 (95% CI: 1.27–2.28). Subjects with ALL (p value for
trend = 0.025) and subjects with CML (p value for
trend = 0.031) displayed signiﬁcant gradients in the rela-
tionship between nSES and mortality. For CML, adjusted
hazard ratios were higher at every lower quintile of nSES
(highest nSES quintile = reference group; second highest
nSES HR: 1.25, 95% CI: 0.74–2.11; middle nSES HR:
1.58, 95% CI: 0.95–2.63; second poorest nSES HR: 1.78,
95% CI: 1.06–2.99; poorest nSES HR: 2.10, 95% CI: 1.27–
3.49). Not having insurance or having unknown insurance
status contributed to worse survival for subjects with
ALL (adjusted HR: 1.37, 95% CI: 1.16–1.62) and AML
(adjusted HR: 1.31, 95% CI: 1.09–1.57), but not for those
with CML.
Discussion
Our study demonstrated pronounced lower overall survival
in young individuals with leukemia living in lower-SES
neighborhoods, in adolescents and young adults when
compared to children, in NHBs and HLs when compared to
NHWs, and in patients uninsured at the time of diagnosis.
Further, stratiﬁed survival analyses indicated a socioeco-
nomic gradient in survival that was observed only in 30–39
year-old patients, those diagnosed with CML, and NHW
patients.
The rather drastic differences we found in survival for
ALL among age groups have been previously documented,
with worse survival for adolescents aged 15–19 than for
children [25]. We found that survival differences also
varied among the four major race/ethnicities in California,
with NHBs faring the worst for both ALL and AML. The
gradient we found between area-level SES and survival
has been shown in other registry-based studies of cancer,
Fig. 1 Kaplan–Meier
univariate overall survival
curves for California leukemia
cases aged 0–39 diagnosed from
1996 to 2005 modiﬁed by: a age
group, b insurance status at
diagnosis, c race/ethnicity, and
d neighborhood socioeconomic
status (nSES)
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Fig. 2 Five-year survival proportion by each year of age at diagnosis
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123including melanoma [26] and pancreatic cancer [27].
However, the nSES gradient in our study was signiﬁcant
only in NHWs. Our study consisted of one of the largest
sample sizes of API patients with leukemia, and it is
noteworthy that there did not appear to be a consistent
relationship between nSES and survival in this race/ethnic
group.
In addition, the lack of an nSES gradient in survival
among Hispanics/Latinos was surprising and raises many
questions. Of the cases residing in the lowest SES neigh-
borhoods at diagnosis, 80.5% were HL, with most HL
patients residing in the lowest (45.4%) or second lowest
nSES (24.2%) areas. A report on state-based variations in
access to care and use of preventive services found that the
percentage of individuals in California who obtained a
routine checkup in 1997–2004 compared to 1991–1996 had
declined signiﬁcantly for HLs, but risen signiﬁcantly for
NHWs [28]. Thus, some of the survival disparity observed
for HLs may reﬂect restricted access to care for this ethnic
group, regardless of nSES. Future research should consider
possible barriers to care that the current study was unable
to determine, such as generational status and primary lan-
guage spoken at home, which may impact health-seeking
behavior in HLs [29]. The existing nSES gradient for
NHWs found in the current study suggests, however, that a
delivery gap may indeed persist for some young individ-
uals with leukemia, experienced most acutely by older
adolescents and young adults.
From our analysis alone, we could not determine whe-
ther there are true biological differences for young HL
patients with leukemia compared to other racial/ethnic
groups or whether even bigger differences exist with
aforementioned variables such as access to treatment, trial
participation, and education. Aplenc et al. [2] demonstrated
Table 3 Multivariate hazard ratios comparing overall survival (OS) among age groups using Cox proportional hazards model
Characteristic Age group
0–14 15–29 30–39
n HR 95% CI n HR 95% CI n HR 95% CI
Race/ethnicity
Non-Hispanic white 1,379 1.00 (Ref) – 617 1.00 (Ref) – 693 1.00 (Ref) –
Non-Hispanic black 178 1.54* (1.12–2.13) 98 1.48* (1.08–2.03) 112 1.26 (0.93–1.72)
Hispanic/Latino 2,178 1.34* (1.12–1.63) 936 1.13 (0.94–1.36) 646 1.19 (0.98–1.43)
Asian/Paciﬁc Islander 385 1.19 (0.91–1.56) 191 1.17 (0.90–1.52) 201 1.11 (0.86–1.44)
Leukemia type
ALL 3,409 1.00 (Ref) – 877 1.00 (Ref) – 409 1.00 (Ref) –
AML 675 3.59* (3.08–4.19) 700 1.17 (1.00–1.36) 762 0.69* (0.58–0.81)
CML 72 2.97* (1.96–4.49) 272 0.60* (0.47–0.77) 421 0.32* (0.26–0.40)
nSES
Highest 669 1.00 (Ref) – 237 1.00 (Ref) – 283 1.00
  (Ref) –
High 677 1.15 (0.88–1.50) 321 0.86 (0.65–1.14) 326 1.33* (1.01–1.76)
Middle 747 0.99 (0.75–1.30) 350 1.11 (0.85–1.45) 324 1.52* (1.15–2.01)
Low 877 1.09 (0.84–1.43) 321 0.99 (0.75–1.30) 328 1.48* (1.12–1.95)
Lowest 1,118 1.13 (0.86–1.47) 533 1.22 (0.93–1.60) 400 1.55* (1.18–2.05)
Insurance
Any 3,797 1.00 (Ref) – 1,542 1.00 (Ref) – 1,430 1.00 (Ref) –
None/unknown 361 1.56* (1.26–1.94) 315 1.24* (1.02–1.49) 241 1.18 (0.96–1.47)
Treatment hospital type
Other 1,346 1.00 (Ref) – 1,397 1.00 (Ref) – 1,406 1.00 (Ref) –
Pediatric hospital 1,900 1.01 (0.85–1.18) 165 1.01 (0.77–1.31) 0 – –
Pediatric afﬁliate hospital 910 0.91 (0.74–1.11) 287 0.87 (0.70–1.07) 186 0.95 (0.75–1.21)
Source: California Cancer Registry. Individuals diagnosed between 1 January 1996 and 31 December 2005
All hazard ratios are fully adjusted for the other variables in the model, in addition to gender and diagnostic year
Results for individuals with race/ethnicity other than what is listed (n = 63) are suppressed from output
nSES neighborhood socioeconomic status, OS overall survival, HR hazard ratio, CI conﬁdence interval, Ref reference
OS: n=7,597, with 5,410 observations censored
* Signiﬁcant at p\0.05;
  signiﬁcant for trend, p\0.05
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123that African American and Hispanic children with AML
had worse OS rates than NHWs in a randomized, con-
trolled clinical trial. Further, a cytogenetic study found a
signiﬁcantly lower frequency of TEL-AML1 translocations
(a polymorphism thought to be protective) in HL when
compared to NHW children with B-cell ALL [30].
The age group survival disparity we noted has been
found in other cancers in the AYA group, along with a lack
of measurable progress in survival improvements in 15- to
29-year-olds relative to all other age groups [4, 15]. Rea-
sons may include the lower rates of enrollment for older
teenagers in clinical trials and studies than younger chil-
dren [4, 31]. During the 1990s, only 10–20% of 15- to 19-
year-olds and fewer than 2% of 20- to 29-year-olds with
cancer participated in cancer clinical trials in the United
States, compared with 55–65% of 0- to 14-year-olds [32].
Whether a patient enrolls on a clinical trial or not, 15- to
29-year-old patients are less likely to see providers from
research institutions, which may contribute to worse out-
comes [31], and AYAs are often put on adult rather than
pediatric treatment regimens, which may ultimately be less
effective [33–36]. A recently conducted trial in which the
ALL-96 pediatric protocol was administered to 35 ado-
lescents (15- to 18-year-old) and 46 young adults (19- to
30-year-old) found that despite a slight increase in hema-
tologic toxicity, the results were comparable for both
groups, warranting usage of the more effective protocol in
these older age groups [37].
Although our study covers an ethnically diverse popu-
lation, which may be appropriate for comparison to other
geographic areas, there are some state-speciﬁc factors that
may be unique to our population. Adolescents and young
adults age out of pediatric hospital systems, which provide
care only for individuals aged 21 and under [38]. Individ-
uals under the age of 21 in California are eligible for health
coverage plans to supplement Medicaid, such as the
Table 4 Multivariate hazard ratios comparing overall survival among race/ethnicities using Cox proportional hazards model
Characteristic Race/ethnicity
Non-Hispanic white Non-Hispanic black Hispanic/Latino Asian/Paciﬁc Islander
n HR 95% CI n HR 95% CI n HR 95% CI n HR 95% CI
Age group
0–14 1,377 1.00 (Ref) – 178 1.00 (Ref) – 2,178 1.00
(Ref)
– 385 1.00
(Ref)
–
15–29 615 2.68* (2.19–3.28) 97 2.03* (1.07–3.86) 933 2.71* (2.34–3.14) 191 2.54* (1.79–3.62)
30–39 647 2.80* (2.26–3.48) 106 2.40* (1.58–3.63) 633 3.25* (2.74–3.86) 194 2.64* (1.82–3.85)
Leukemia type
ALL 1,529 1.00 (Ref) – 178 1.00 (Ref) – 2,542 1.00
(Ref)
– 408 1.00
(Ref)
–
AML 810 1.56* (1.30–1.87) 149 1.55* (1.07–2.26) 915 1.40* (1.22–1.61) 252 1.35* (0.98–1.87)
CML 300 0.68* (0.52–0.90) 54 0.47* (0.26–0.86) 287 0.62* (0.48–0.78) 110 0.72 (0.47–1.13)
nSES
Highest 711 1.00
  (Ref) – 23 1.00 (Ref) – 193 1.00
(Ref)
– 214 1.00
(Ref)
–
High 680 1.17 (0.94–1.45) 63 1.77 (0.66–4.73) 363 0.92 (0.67–1.26) 190 0.97 (0.65–1.46)
Middle 593 1.26* (1.01–1.57) 86 1.53 (0.59–3.96) 580 0.88 (0.66–1.19) 135 1.50 (1.00–2.24)
Low 435 1.34* (1.06–1.70) 119 1.99 (0.78–5.04) 904 0.87 (0.66–1.19) 138 1.20 (0.79–1.82)
Lowest 220 1.38* (1.04–1.70) 90 2.23 (0.87–5.68) 1,704 0.98 (0.75–1.28) 93 1.65* (1.06–2.56)
Insurance
Any 2,453 1.00 (Ref) – 324 1.00 (Ref) – 3,158 1.00
(Ref)
– 701 1.00
(Ref)
–
None/
unknown
186 1.54* (1.20–1.98) 57 1.69* (1.09–2.63) 586 1.21* (1.04–1.41) 69 1.42 (0.94–2.13)
Source: California Cancer Registry. Individuals diagnosed between 1 January 1996 and 31 December 2005
All hazard ratios are fully adjusted for the other variables in the model, in addition to gender and diagnostic year
Results for individuals with race/ethnicity other than what is listed (n = 63) are suppressed from output
OS: n=7,597, with 5,410 observations censored
nSES neighborhood socioeconomic status, OS overall survival, HR hazard ratio, CI conﬁdence interval, Ref reference
* Signiﬁcant at p\0.05;
  signiﬁcant for trend, p\0.05
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123California Children Services (CCS), which may improve
cancer care and mitigate the relationship we found between
nSES and survival. The plan requires that enrollees be
cared for by a CCS physician; for CCS patients with can-
cer, most of the afﬁliated physicians are pediatric oncolo-
gists. Several studies have demonstrated that pediatric
oncologists generally follow clinical trial protocols, which
tend to improve survival for AYAs when compared to
standard adult treatment regimens [33–36]. Thus, it is
possible that age-speciﬁc insurance availability in Cali-
fornia may at least partially explain why we did not ﬁnd a
signiﬁcant survival gradient with increasing nSES for the
15–29 age group.
Strengths and limitations
This study is the ﬁrst to examine age group, race/ethnicity,
and neighborhood socioeconomic differences in survival
among young leukemia patients from such a large popu-
lation. The large number of person-years in the CCR allows
for high-powered analyses of several factors that might
affect survivorship and that may be relevant for young
patients with leukemia outside of California.
It is possible that there was a degree of under-ascer-
tainment of death in our study; however, every individual
contributed a certain amount of survival time before they
either died or were censored and patients were followed up
annually. Thus, it is unlikely that patients would have been
mistakenly assumed to be alive year after year if they were,
in fact, deceased. Any misclassiﬁcation of outcome that
resulted from under-ascertainment of death would have
likely biased our ﬁndings toward the null, as we would
have expected that lower-SES patients would be more
likely to die without death ascertainment. If there were
more low-SES patients who had died but had been classi-
ﬁed as censored, then it is possible that we underestimated
the relationship between lower SES and risk of death. Only
ten (0.13%) of the individuals included in the analysis had
an unknown source of last patient follow-up, so this pos-
sibility is unlikely.
Additional limitations of this study include some likely
misclassiﬁcation of exposure, particularly with the nSES
Table 5 Multivariate hazard ratios comparing overall survival among leukemia types using Cox proportional hazards model
Characteristic Leukemia type
ALL AML CML
n HR 95% CI n HR 95% CI n HR 95% CI
Age group
0–14 3,409 1.00 (Ref) – 675 1.00 (Ref) – 72 1.00 (Ref) –
15–29 877 3.90* (3.40–4.48) 700 1.25* (1.06–1.48) 272 0.77 (0.48–1.22)
30–39 409 6.94* (5.91–8.14) 762 1.24* (1.05–1.46) 421 0.71 (0.46–1.11)
Race/ethnicity
Non-Hispanic white 1,529 1.00 (Ref) – 810 1.00 (Ref) – 300 1.00 (Ref) –
Non-Hispanic black 178 1.70* (1.27–2.28) 149 1.36* (1.06–1.76) 54 0.91 (0.52–1.59)
Hispanic/Latino 2,542 1.30* (1.11–1.52) 915 1.14 (0.97–1.35) 287 1.24 (0.89–1.75)
Asian/Paciﬁc Islander 408 1.26 (0.99–1.60) 252 1.02 (0.82–1.28) 110 1.45 (0.97–2.18)
nSES
Highest 721 1.00
  (Ref) – 319 1.00 (Ref) – 125 1.00
  (Ref) –
High 768 1.18 (0.93–1.48) 381 1.01 (0.79–1.28) 157 1.25 (0.74–2.11)
Middle 830 1.06 (0.83–1.34) 415 1.26 (1.00–1.58) 156 1.58 (0.95–2.63)
Low 995 1.11 (0.88–1.40) 476 1.15 (0.91–1.45) 140 1.78* (1.06–2.99)
Lowest 1,381 1.35* (1.08–1.69) 546 1.10 (0.86–1.40) 187 2.10* (1.27–3.49)
Insurance
Any 4,192 1.00 (Ref) – 1,846 1.00 (Ref) – 649 1.00 (Ref) –
None/unknown 503 1.37* (1.16–1.62) 291 1.31* (1.09–1.57) 119 1.00 (0.67–1.49)
Source: California Cancer Registry. Individuals diagnosed between 1 January 1996 and 31 December 2005
All hazard ratios are fully adjusted for the other variables in the model, in addition to gender and diagnostic year
Results for individuals with race/ethnicity other than what is listed (n = 63) are suppressed from output
OS: n=7,597, with 5,410 observations censored
nSES neighborhood socioeconomic status, OS overall survival, HR hazard ratio, CI conﬁdence interval, Ref reference
* Signiﬁcant at p\0.05;
  signiﬁcant for trend, p\0.05
Cancer Causes Control (2009) 20:1409–1420 1417
123variable used, although we expect the effect to be non-
differential with respect to survival and age groupings.
Because nSES was assigned by residence at diagnosis, a
portion of the cases may have been assigned a neighbor-
hood score that was not truly representative of their per-
sonal overall access to resources. If there is a lot of
heterogeneity within block groups, then the probability of
exposure misclassiﬁcation would be increased in our study;
however, census blocks are considered relatively homog-
enous in demographics, with most variation attributable
between tracts [39]. Looking at resources on only an
aggregate level limits the ability to compare the efﬁcacy of
the presence of structural resources (proximity to quality
treatment facilities, the ability to be included on a research
trial) with individual ability to gain access to those
resources. On the other hand, only focusing on individuals
ignores the broader issues of neighborhood contextual
effects on health, such as community resources for healthy
living [40]. Previous studies on incidence and survival
based on CCR data have tended to use ecological measures
of SES [26, 27, 41, 42]. Evidence suggests, however, that
personally reported SES dominates area-level measures
and that predictive value can only be gained by including
area-level SES when behavioral and biological risk factors
are not known [43], as was the case in our study.
The neighborhood SES effects on survival that we
documented in some of the sub-groups may be a proxy for
the types of treatment options available for individuals in
certain low resourced areas, for example, having the option
of admittance to a pediatric hospital. Previous research has
documented the beneﬁts of treatment for AYA leukemia
patients at pediatric hospitals [38]. We did not see any
signiﬁcant protection for treatment at a pediatric hospital or
pediatric-afﬁliated hospital in the group for which we
included this variable, individuals aged 0–14. This may be
an overly simplistic way to look at treatment hospital type;
there may be substantial inter-hospital variability with
respect to treatment success beyond whether or not the
institution specializes in pediatrics, and registry analyses
might not be the best method to address these questions.
Conclusions
Our study demonstrated the importance of age group, race/
ethnicity, nSES, and insurance status on survival of young
people with leukemia. We found that the differences in
survival across race/ethnicities and age groups persisted
after adjustment for nSES and insurance status, which
suggests the possibility of important biological differences
across these groups. In addition, the dose-response gradient
we observed between nSES and survival warrants further
investigation into healthcare access and clinical trial
participation. Future research is needed to address the
survival disparities observed by focusing on variables
relevant to children, adolescents, and young adults with
cancer, as outlined by the National Cancer Institute and
Lance Armstrong Foundation’s joint Adolescent and
Young Adult Oncology Progress Review Group [38]. We
encourage future studies to further explore both individual-
and neighborhood-level socioeconomic barriers and to
examine access to care for diverse racial/ethnic AYA
populations.
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